company background image
HYPE3 logo

Hypera BOVESPA:HYPE3 Stock Report

Last Price

R$28.74

Market Cap

R$18.2b

7D

0.1%

1Y

-36.4%

Updated

16 Jun, 2024

Data

Company Financials +

Hypera S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hypera
Historical stock prices
Current Share PriceR$28.74
52 Week HighR$46.84
52 Week LowR$26.72
Beta0.40
1 Month Change-5.24%
3 Month Change-13.72%
1 Year Change-36.40%
3 Year Change-20.83%
5 Year Change-3.23%
Change since IPO244.19%

Recent News & Updates

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 16
Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 16
Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Is Hypera (BVMF:HYPE3) A Risky Investment?

Feb 21
Is Hypera (BVMF:HYPE3) A Risky Investment?

Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Jan 09
Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Dec 22
Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Nov 02
Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Aug 27
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Is Hypera (BVMF:HYPE3) A Risky Investment?

Jul 21
Is Hypera (BVMF:HYPE3) A Risky Investment?

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Apr 15
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

Feb 19
With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Jan 03
We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Oct 11
Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Jul 19
Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Jun 28
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

Apr 14
Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Mar 25
I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Mar 04
Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Shareholder Returns

HYPE3BR PharmaceuticalsBR Market
7D0.1%-0.4%-1.6%
1Y-36.4%-28.4%-4.5%

Return vs Industry: HYPE3 underperformed the BR Pharmaceuticals industry which returned -28.4% over the past year.

Return vs Market: HYPE3 underperformed the BR Market which returned -4.5% over the past year.

Price Volatility

Is HYPE3's price volatile compared to industry and market?
HYPE3 volatility
HYPE3 Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement4.6%
10% most volatile stocks in BR Market9.2%
10% least volatile stocks in BR Market2.2%

Stable Share Price: HYPE3 has not had significant price volatility in the past 3 months.

Volatility Over Time: HYPE3's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199910,301Breno Pires de Oliveirawww.hypera.com.br

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.

Hypera S.A. Fundamentals Summary

How do Hypera's earnings and revenue compare to its market cap?
HYPE3 fundamental statistics
Market capR$18.19b
Earnings (TTM)R$1.70b
Revenue (TTM)R$8.04b

10.7x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HYPE3 income statement (TTM)
RevenueR$8.04b
Cost of RevenueR$3.02b
Gross ProfitR$5.02b
Other ExpensesR$3.32b
EarningsR$1.70b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 25, 2024

Earnings per share (EPS)2.69
Gross Margin62.47%
Net Profit Margin21.14%
Debt/Equity Ratio90.5%

How did HYPE3 perform over the long term?

See historical performance and comparison

Dividends

4.3%

Current Dividend Yield

42%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.